Originally published by our sister publication Infectious Disease Special Edition
By IDSE News Staff
The FDA granted approval to nirsevimab-alip (Beyfortus, Sanofi/AstraZeneca) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season.
Nirsevimab-alip is also now indicated for children up to 24 months of age who are vulnerable to severe RSV disease through their second RSV season.
It is the first and